Table 3.
Summary of measures of quality of care for HIV/AIDS in study populations with serious mental illness (SMI), United States 2000–2013
| PANEL 1: ADHERENCE TO GUIDELINES FOR CARE AND TREATMENT OF HIV/AIDS | |||||
|---|---|---|---|---|---|
| Measure | Studies (N) | Measures Abstracted (N) | Measure range in population with SMI | Guideline Adherence in Study Samples with and without SMI (N Measures) | Studies Reviewed |
| Percent of Patients Receiving: | |||||
| CD4 Count Monitoring | 1 | 2 | 85% | More likely in SMI population: 0 Less likely in SMI population: 0 No difference: 1 |
(Bogart et al., 2006) |
| Viral Load Monitoring | 1 | 2 | 82% | More likely in SMI population: 0 Less likely in SMI population: 0 No difference: 1 |
(Bogart et al., 2006) |
| Antiretroviral therapy1 | 4 | 12 | 51%–83% | More likely in SMI population: 0 Less likely in SMI population: 2 No difference: 1 |
(Bogart et al., 2006; Himelhoch et al., 2007; Walkup et al., 2001; Walkup et al., 2004) |
1
Includes highly active antiretroviral therapy (HAART), protease inhibitors (PIs), and non-nucleoside reverse transcriptase inhibitors (NNRTIs)